Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 51.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,350 shares of the company's stock after selling 4,550 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Medpace were worth $1,445,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Lindbrook Capital LLC increased its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its position in Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after buying an additional 29 shares in the last quarter. Assetmark Inc. raised its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after acquiring an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. grew its stake in shares of Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after acquiring an additional 30 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of MEDP traded down $10.03 during trading hours on Wednesday, hitting $296.60. 105,487 shares of the stock were exchanged, compared to its average volume of 350,131. The company has a market cap of $8.52 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The stock's 50-day moving average price is $303.64 and its two-hundred day moving average price is $327.62.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the prior year, the business earned $3.20 earnings per share. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MEDP. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Mizuho reduced their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird decreased their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Leerink Partners started coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.